| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| BBNXBeta Bionics, Inc. | 783.2M | 17.79 | -2.07 | 442.93% | -87.89% | -26.41% | 0.10 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 179K | 11.99M | 65.12M |
| Revenue Growth % | - | 66.01% | 4.43% |
| Cost of Goods Sold | 0 | 5.69M | 29.24M |
| COGS % of Revenue | - | 0.47% | 0.45% |
| Gross Profit | 179K | 6.31M | 35.89M |
| Gross Margin % | 1% | 0.53% | 0.55% |
| Gross Profit Growth % | - | 34.24% | 4.69% |
| Operating Expenses | 66.02M | 42.16M | 81.14M |
| OpEx % of Revenue | 368.84% | 3.51% | 1.25% |
| Selling, General & Admin | 33.49M | 24.21M | 54.95M |
| SG&A % of Revenue | 187.12% | 2.02% | 0.84% |
| Research & Development | 31.43M | 17.94M | 26.18M |
| R&D % of Revenue | 175.58% | 1.5% | 0.4% |
| Other Operating Expenses | 1.1M | 0 | 0 |
| Operating Income | -65.84M | -35.85M | -45.25M |
| Operating Margin % | -367.84% | -2.99% | -0.69% |
| Operating Income Growth % | - | 0.46% | -0.26% |
| EBITDA | -64.5M | -34.62M | -44.1M |
| EBITDA Margin % | -360.33% | -2.89% | -0.68% |
| EBITDA Growth % | - | 0.46% | -0.27% |
| D&A (Non-Cash Add-back) | 1.34M | 1.23M | 1.15M |
| EBIT | -64.74M | -35.85M | -45.25M |
| Net Interest Income | 182K | 1.78M | 3.91M |
| Interest Income | 196K | 1.78M | 3.91M |
| Interest Expense | 14K | 0 | 0 |
| Other Income/Expense | 1.09M | -8.25M | -9.51M |
| Pretax Income | -64.75M | -44.1M | -54.76M |
| Pretax Margin % | -361.74% | -3.68% | -0.84% |
| Income Tax | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% |
| Net Income | -64.75M | -44.1M | -54.76M |
| Net Margin % | -361.74% | -3.68% | -0.84% |
| Net Income Growth % | - | 0.32% | -0.24% |
| Net Income (Continuing) | -64.75M | -44.1M | -54.76M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -12.96 | -8.31 | -8.60 |
| EPS Growth % | - | 0.36% | -0.03% |
| EPS (Basic) | -12.96 | -8.31 | -8.60 |
| Diluted Shares Outstanding | 5M | 5.3M | 6.37M |
| Basic Shares Outstanding | 5M | 5.3M | 6.37M |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 28.47M | 103.62M | 132.92M |
| Cash & Short-Term Investments | 27.68M | 96.75M | 103.58M |
| Cash Only | 27.68M | 26.57M | 30.43M |
| Short-Term Investments | 0 | 70.18M | 73.14M |
| Accounts Receivable | 0 | 4.45M | 12M |
| Days Sales Outstanding | - | 135.35 | 67.23 |
| Inventory | 0 | 1.25M | 13.32M |
| Days Inventory Outstanding | - | 79.91 | 166.29 |
| Other Current Assets | 250K | 275K | 1.05M |
| Total Non-Current Assets | 7.06M | 6.42M | 16.72M |
| Property, Plant & Equipment | 6.87M | 6.2M | 11.42M |
| Fixed Asset Turnover | 0.03x | 1.94x | 5.70x |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 193K | 221K | 5.3M |
| Total Assets | 35.53M | 110.04M | 149.65M |
| Asset Turnover | 0.01x | 0.11x | 0.44x |
| Asset Growth % | - | 2.1% | 0.36% |
| Total Current Liabilities | 8.87M | 10.61M | 21.15M |
| Accounts Payable | 430K | 1.17M | 2.85M |
| Days Payables Outstanding | - | 74.84 | 35.61 |
| Short-Term Debt | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 939K |
| Other Current Liabilities | 1.32M | 1.14M | 10.94M |
| Current Ratio | 3.21x | 9.77x | 6.29x |
| Quick Ratio | 3.21x | 9.65x | 5.66x |
| Cash Conversion Cycle | - | 140.42 | 197.92 |
| Total Non-Current Liabilities | 13.65M | 40.83M | 52.48M |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 3.16M | 3M | 5.73M |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 10.5M | 37.83M | 44.9M |
| Total Liabilities | 22.53M | 51.43M | 73.63M |
| Total Debt | 4.13M | 4.22M | 7.25M |
| Net Debt | -23.54M | -22.34M | -23.18M |
| Debt / Equity | 0.32x | 0.07x | 0.10x |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | -4703.14x | - | - |
| Total Equity | 13M | 58.61M | 76.01M |
| Equity Growth % | - | 3.51% | 0.3% |
| Book Value per Share | 2.60 | 11.05 | 11.94 |
| Total Shareholders' Equity | 13M | 58.61M | 76.01M |
| Common Stock | 1K | 1K | 1K |
| Retained Earnings | -185.56M | -229.66M | -296.74M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 0 | 137K | 65K |
| Minority Interest | 0 | 0 | 0 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -60.21M | -32.45M | -48.27M |
| Operating CF Margin % | -336.36% | -2.7% | -0.74% |
| Operating CF Growth % | - | 0.46% | -0.49% |
| Net Income | -64.75M | -44.1M | -54.76M |
| Depreciation & Amortization | 2.09M | 2.09M | 2.28M |
| Stock-Based Compensation | 6.1M | 5.66M | 6.38M |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | -854K | 10.27M | 9.96M |
| Working Capital Changes | -2.79M | -6.36M | -12.15M |
| Change in Receivables | 0 | -4.49M | -7.62M |
| Change in Inventory | 0 | -1.19M | -11.44M |
| Change in Payables | -77K | 0 | 1.51M |
| Cash from Investing | -769K | -69.69M | -3.48M |
| Capital Expenditures | -772K | -402K | -3.4M |
| CapEx % of Revenue | 4.31% | 0.03% | 0.05% |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | 3K | -69.29M | 50K |
| Cash from Financing | 56.78M | 101.03M | 55.62M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | 389K | 101.03M | 0 |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -60.98M | -32.85M | -51.67M |
| FCF Margin % | -340.67% | -2.74% | -0.79% |
| FCF Growth % | - | 0.46% | -0.57% |
| FCF per Share | -12.20 | -6.19 | -8.12 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.74x | 0.88x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Return on Equity (ROE) | -498.08% | -123.17% | -81.35% |
| Return on Invested Capital (ROIC) | - | -209.05% | -76.18% |
| Gross Margin | 100% | 52.59% | 55.11% |
| Net Margin | -36173.74% | -367.64% | -84.08% |
| Debt / Equity | 0.32x | 0.07x | 0.10x |
| Interest Coverage | -4703.14x | - | - |
| FCF Conversion | 0.93x | 0.74x | 0.88x |
| Revenue Growth | - | 6601.12% | 442.93% |
Beta Bionics, Inc. (BBNX) reported $88.6M in revenue for fiscal year 2024. This represents a 49380% increase from $0.2M in 2022.
Beta Bionics, Inc. (BBNX) grew revenue by 442.9% over the past year. This is strong growth.
Beta Bionics, Inc. (BBNX) reported a net loss of $77.8M for fiscal year 2024.
Beta Bionics, Inc. (BBNX) has a return on equity (ROE) of -81.3%. Negative ROE indicates the company is unprofitable.
Beta Bionics, Inc. (BBNX) had negative free cash flow of $60.5M in fiscal year 2024, likely due to heavy capital investments.